ESR2 and neoplasm: Despite increasing evidence that ERβ1 acts as a tumor suppressor in hormone-dependent cancers, comprehensive investigation of ESR2 nsSNPs—especially within the LBD, DBD, and AF-1/AF-2 domains—remains limited, hindering the clinical application of variant profiling.